Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Moderna Set to Sell 160 Million Coronavirus Vaccine Doses to EU

By Brian Orelli, PhD - Nov 24, 2020 at 1:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its vaccine candidate, mRNA-1273, still needs to be approved by health regulators.

Score another pre-approval sale for coronavirus vaccine-maker Moderna ( MRNA 1.53% ). European Commission President Ursula von der Leyen has announced that the EC will ink a deal with the company on Wednesday. The contract will allow the European Union's member countries to purchase up to 160 million doses of Moderna's COVID-19 vaccine, mRNA-1273, once the vaccine is approved by EU regulators.

Moderna has also inked a 100-million-dose supply deal with the U.S. government, with an option for up to 400 million additional doses. Japan has committed to buying 50 million doses in a three-way deal with Japanese drugmaker Takeda Pharmaceutical, which will import the vaccine. 

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Among those coronavirus vaccine developers that are already conducting late-stage clinical trials, Moderna is one of the last to strike a deal with the EU. Earlier this month, the EC signed a contract for 200 million doses of Pfizer ( PFE 1.95% ) and BioNTech's ( BNTX 2.88% ) vaccine, with an option to request an additional 100 million doses. Johnson & Johnson ( JNJ 1.06% ), which is a bit  behind the leaders on the clinical trial front, had its EU contract wrapped up in early October. It will supply the EU with 200 million doses of its vaccine, assuming it passes regulatory muster. And AstraZeneca ( AZN -1.10% ), which announced positive late-stage results this week, signed a 400-million-dose deal back in June with Europe's Inclusive Vaccines Alliance (IVA), which is spearheaded by Germany, France, Italy, and the Netherlands.

The financial terms of the deals haven't been disclosed, but the difference in timing could have to do with the drugmakers' financial situations. Both AstraZeneca and Johnson & Johnson have pledged that they will not price their coronavirus vaccines to make a profit during the pandemic. Pfizer, BioNTech, and Moderna have made no such commitments. It would therefore make sense that the EC and IVA would jump on the opportunity to get AstraZeneca's and Johnson & Johnson's vaccines at cost, while negotiations over prices with the other companies might take more time.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$306.10 (1.53%) $4.61
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.07 (1.95%) $1.03
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$158.75 (1.06%) $1.66
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.19 (-1.10%) $0.60
BioNTech SE Stock Quote
BioNTech SE
BNTX
$343.10 (2.88%) $9.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.